Stock Market News2 months LLY’s Zepbound Outshines NVO’s Wegovy in Head-to-Head Obesity Study Zacks
LLY’s obesity drug, Zepbound, shows an average weight loss of 20.2%, superior to 13.7% for NVO’s Wegovy in a head-to-head study.
XLLY’s obesity drug, Zepbound, shows an average weight loss of 20.2%, superior to 13.7% for NVO’s Wegovy in a head-to-head study.
X